Hereditary hemorrhagic telangiectasia has never had an approved treatment anywhere in the world -- until now, Vaderis Therapeutics launched HEROIC, the first-ever global Phase 3 clinical trial for HHT, backed by $152 million in new funding and proof-of-concept data showing 41% bleeding reduction Swiss biotech Vaderis Therapeutics announced today that it has closed an oversubscribed $152 million Series B financing round and simultaneously launched HEROIC, the first-ever global Phase 3 clinical trial specifically designed to win regulatory approval for a drug targeting hereditary hemorrhagic telangiectasia (HHT). The announcement came via press release. The disease has been recognized since the 19th century, carries the names of three physicians who independently described it between 1896 and 1907, and has never once had an approved pharmacological treatment anywhere in the world. That record of therapeutic abandonment — the longest per-patient unmet need of any disease classified as the second most common inherited bleeding disorder — is what HEROIC is designed to end. Managing a reversible rash and monitoring blood sugar is a different clinical reality than managing broad-spectrum kinase off-target toxicity in a non-cancer population. The scientific foundation for HEROIC is unusually strong for a Phase 3 launch in rare disease. The full investor list and CEO statement appear in the August 11, 2026 press release. The round was described as oversubscribed — meaning investor demand exceeded the offered raise, a meaningful signal in a selective clinical-stage rare disease financing market. Its success or failure will determine whether AKT inhibition becomes a third oncology drug class with validated non-malignant rare disease applications — joining mTOR and MEK as confirmed disease-modifying mechanisms beyond tumor biology. The implications extend beyond HHT: PIK3CA-related overgrowth spectrum, PTEN hamartoma tumor syndrome, and other rare conditions driven by PI3K/AKT pathway hyperactivation share mechanistic kinship with HHT's AKT excess, and HEROIC's outcome will shape whether AKT inhibitors enter clinical development for those diseases as well.

Drug developers Seaport Therapeutics and Hemab Therapeutics launched their U.S. initial public offerings on Monday, seeking ​to capitalize on a growing investor appetite for new listings. Earlier on ​Monday, space analytics firm HawkEye 360 and organic juice maker Suja Life ⁠also launched their IPOs, as issuers moved quickly to tap ​the reopening window. Pulmonary fibrosis biotech Avalyn Pharma also launched its U.S. IPO last ​week. Boston-based Seaport is seeking to raise up to $212.4 million by offering 11.8 million shares priced between $16 and $18 each, which could value the company at up to ​about $912 million. The clinical-stage biotech is developing oral therapies for depression, ​anxiety and other neuropsychiatric disorders. Hemab is ​focused on treatments for rare blood-clotting and bleeding ​disorders. Its ⁠lead candidate is being developed as a preventive treatment for rare inherited bleeding disorders Glanzmann thrombasthenia and Factor VII deficiency.